BioLineRx(BLRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue to the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28][29] Question: Enthusiasm from principal investigators for GLIX1 trial - There is significant enthusiasm from investigators regarding GLIX1's novel mechanism of action and preclinical results, with eagerness to initiate the study [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway, but no interim readouts expected due to the study's blinded nature [44][46] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients, typically having exhausted standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]